AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June

Can-Fite BioPharma Ltd. expects to report data from a phase II trial of CF101, conducted by its subsidiary OphthaliX, in the treatment of glaucoma and related syndromes of ocular hypertension next month.

from RTT - Biotech http://ift.tt/1WU6csu
via IFTTT